CN101478952A - 凝胶剂形式的含罗匹尼洛的药物组合物及其应用 - Google Patents

凝胶剂形式的含罗匹尼洛的药物组合物及其应用 Download PDF

Info

Publication number
CN101478952A
CN101478952A CNA2007800229856A CN200780022985A CN101478952A CN 101478952 A CN101478952 A CN 101478952A CN A2007800229856 A CNA2007800229856 A CN A2007800229856A CN 200780022985 A CN200780022985 A CN 200780022985A CN 101478952 A CN101478952 A CN 101478952A
Authority
CN
China
Prior art keywords
ropinirole
gel
skin
transdermal
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800229856A
Other languages
English (en)
Chinese (zh)
Inventor
吉恩·贾米森
达里奥·诺尔贝托·卡拉拉
阿诺·格勒尼耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Inc
Original Assignee
Jazz Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Inc filed Critical Jazz Pharmaceuticals Inc
Publication of CN101478952A publication Critical patent/CN101478952A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2007800229856A 2006-06-29 2007-06-26 凝胶剂形式的含罗匹尼洛的药物组合物及其应用 Pending CN101478952A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81725906P 2006-06-29 2006-06-29
US60/817,259 2006-06-29

Publications (1)

Publication Number Publication Date
CN101478952A true CN101478952A (zh) 2009-07-08

Family

ID=38895093

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800229856A Pending CN101478952A (zh) 2006-06-29 2007-06-26 凝胶剂形式的含罗匹尼洛的药物组合物及其应用

Country Status (17)

Country Link
US (1) US20080004329A1 (enExample)
EP (1) EP2032125A2 (enExample)
JP (1) JP2009542657A (enExample)
KR (1) KR20090031598A (enExample)
CN (1) CN101478952A (enExample)
AR (1) AR063201A1 (enExample)
AU (1) AU2007269896A1 (enExample)
BR (1) BRPI0713801A2 (enExample)
CA (1) CA2654383A1 (enExample)
IL (1) IL195161A0 (enExample)
MX (1) MX2008015083A (enExample)
NO (1) NO20085158L (enExample)
NZ (1) NZ572481A (enExample)
PE (1) PE20080374A1 (enExample)
TW (1) TW200815045A (enExample)
UY (1) UY30442A1 (enExample)
WO (1) WO2008005240A2 (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107638562A (zh) * 2009-09-28 2018-01-30 精达制药公司 基本稳态药物递送的快速建立和/或终止
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN116763842A (zh) * 2023-07-11 2023-09-19 海南职业技术学院 一种胆木浸膏凝胶剂及其制备工艺
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212397A1 (en) * 2005-09-15 2007-09-13 Roth Daniel B Pharmaceutical delivery device and method for providing ocular treatment
CA2730787A1 (en) * 2008-07-16 2010-01-21 David M. Cohen Topical drug delivery system
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4, Inc. ADMINISTRATION OF A MEDICATION IN THE POSTERIOR SEGMENT
KR20120024562A (ko) * 2009-04-24 2012-03-14 히사미쓰 세이야꾸 가부시키가이샤 첩부제 수용 포장 백, 및 첩부제의 보존 방법
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
WO2012019136A2 (en) 2010-08-05 2012-02-09 Forsight Vision 4, Inc. Injector apparatus and method for drug delivery
CN103209664A (zh) 2010-08-05 2013-07-17 弗赛特影像4股份有限公司 可植入的治疗装置
CN103153316B (zh) 2010-08-05 2015-08-19 弗赛特影像4股份有限公司 组合药物递送方法和设备
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
CN103476404B (zh) 2011-03-24 2017-09-29 帝国制药美国公司 包含活性剂层和活性剂转化层的透皮组合物
CN103561737A (zh) * 2011-05-31 2014-02-05 久光制药株式会社 含有罗匹尼罗的贴附剂及其包装体
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
SI2755600T1 (sl) 2011-09-16 2021-08-31 Forsight Vision4, Inc. Naprava za izmenjavo tekočine
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
EP3275466A1 (en) 2012-07-12 2018-01-31 Ferring B.V. Diclofenac formulations
AU2013338243B2 (en) 2012-11-02 2016-09-29 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
JP6234936B2 (ja) * 2012-11-30 2017-11-22 帝國製薬株式会社 ロピニロール含有貼付剤
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
AU2014241163B2 (en) 2013-03-28 2018-09-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
EP4245765A3 (en) 2013-04-04 2024-03-20 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
US9463889B2 (en) * 2013-10-25 2016-10-11 Medtronic, Inc. Prefilled reservoir apparatus for ambulatory infusion device
RU2695563C2 (ru) 2014-07-15 2019-07-24 Форсайт Вижн4, Инк. Способ и устройство для доставки глазного имплантата
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
HUE068152T2 (hu) 2014-09-25 2024-12-28 Boehringer Ingelheim Vetmedica Gmbh SGLT2-gátlók és dopamin agonisták kombinációs kezelése anyagcserezavarok megelõzésére lófélékben
JP7037360B2 (ja) 2014-11-10 2022-03-16 フォーサイト・ビジョン フォー・インコーポレーテッド 拡張可能な薬物送達デバイス
US10716763B2 (en) 2015-04-15 2020-07-21 Hisamitsu Pharmaceutical Co., Inc. Transdermal patch containing ropinirole
KR20180084104A (ko) 2015-11-20 2018-07-24 포사이트 비젼4, 인크. 연장 방출 약물 전달 장치를 위한 다공성 구조물
SG11201805570WA (en) 2015-12-30 2018-07-30 Corium Int Inc Systems and methods for long term transdermal administration
BR112018070383A2 (pt) 2016-04-05 2019-02-05 Forsight Vision4 Inc dispositivos para aplicação de fármaco oculares implantáveis
WO2017223402A1 (en) 2016-06-23 2017-12-28 Corium International, Inc. Adhesive matrix with hydrophilic and hydrophobic domains and a therapeutic agent
AU2017301928B2 (en) * 2016-07-27 2023-04-06 Corium, LLC. Donepezil transdermal delivery system
CN115607358A (zh) 2017-11-21 2023-01-17 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
KR102212722B1 (ko) * 2019-12-23 2021-02-08 환인제약 주식회사 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones
DE3522550A1 (de) * 1985-06-24 1987-01-02 Klinge Co Chem Pharm Fab Aufspruehbare pharmazeutische zubereitung fuer die topische anwendung
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
GB8712073D0 (en) * 1987-05-21 1987-06-24 Smith Kline French Lab Medicament
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
GB9511366D0 (en) * 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6321105B1 (en) * 1998-04-08 2001-11-20 Bracco S.P.A. Method for diagnosing neurological, neurodegenerative and psychiatric diseases by magnetic resonance imaging using contrast agents with high magnetic susceptibility and extended plasma half life
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
PT1616561E (pt) * 1999-12-28 2008-07-09 Ajinomoto Kk Preparação antidiabética para administração oral
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
SE0001151D0 (sv) * 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
CA2407031A1 (en) * 2000-04-19 2001-10-25 Lilly Icos Llc Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
US6770297B1 (en) * 2000-05-26 2004-08-03 Unitech Pharmaceuticals, Inc. Controlled release delivery system of solid dosage form
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002246490A1 (en) * 2000-10-12 2002-07-30 Pharmacia And Upjohn Company Method of treating parkinson's disease
AU2002220248A1 (en) * 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US6656882B2 (en) * 2001-02-28 2003-12-02 Oms Investments, Inc. Controlled release products and processes for the preparation thereof
WO2002085335A1 (en) * 2001-04-18 2002-10-31 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
US6833478B2 (en) * 2001-07-13 2004-12-21 Sri International N,N-dinitramide salts as solubilizing agents for biologically active agents
DE10137162A1 (de) * 2001-07-30 2003-02-20 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
GB0125088D0 (en) * 2001-10-18 2001-12-12 Smithkline Beecham Cork Ltd New use
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
DE10250711A1 (de) * 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
US20040157910A1 (en) * 2003-02-10 2004-08-12 Smithkline Beecham Corporation Method of treatment or prophylaxis
US7387788B1 (en) * 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
US20070048360A1 (en) * 2005-08-23 2007-03-01 R Carrara Dario N Pharmaceutical compositions with melting point depressant agents and method of making same

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107638562B (zh) * 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
CN107638562A (zh) * 2009-09-28 2018-01-30 精达制药公司 基本稳态药物递送的快速建立和/或终止
US12115144B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12128021B1 (en) 2016-07-22 2024-10-29 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12263150B2 (en) 2016-07-22 2025-04-01 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11766418B2 (en) 2016-07-22 2023-09-26 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12263151B2 (en) 2016-07-22 2025-04-01 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11826335B2 (en) 2016-07-22 2023-11-28 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12138239B2 (en) 2016-07-22 2024-11-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11896572B2 (en) 2016-07-22 2024-02-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097175B2 (en) 2016-07-22 2024-09-24 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097176B2 (en) 2016-07-22 2024-09-24 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12109186B2 (en) 2016-07-22 2024-10-08 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115143B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115142B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115145B2 (en) 2016-07-22 2024-10-15 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12257223B2 (en) 2016-07-22 2025-03-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12144793B2 (en) 2016-07-22 2024-11-19 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12239625B2 (en) 2016-07-22 2025-03-04 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226388B2 (en) 2016-07-22 2025-02-18 Flamel Ireland Limited Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics
US12186298B2 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226389B2 (en) 2016-07-22 2025-02-18 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226377B2 (en) 2019-03-01 2025-02-18 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12167991B2 (en) 2019-03-01 2024-12-17 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12167992B2 (en) 2019-03-01 2024-12-17 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12303478B2 (en) 2019-03-01 2025-05-20 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12295926B1 (en) 2022-02-07 2025-05-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US12551457B1 (en) 2022-02-07 2026-02-17 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN116763842B (zh) * 2023-07-11 2025-03-04 海南职业技术学院 一种胆木浸膏凝胶剂及其制备工艺
CN116763842A (zh) * 2023-07-11 2023-09-19 海南职业技术学院 一种胆木浸膏凝胶剂及其制备工艺

Also Published As

Publication number Publication date
PE20080374A1 (es) 2008-06-11
WO2008005240A3 (en) 2008-05-08
BRPI0713801A2 (pt) 2012-11-06
AU2007269896A1 (en) 2008-01-10
NZ572481A (en) 2011-03-31
CA2654383A1 (en) 2008-01-10
MX2008015083A (es) 2008-12-10
US20080004329A1 (en) 2008-01-03
UY30442A1 (es) 2008-01-31
EP2032125A2 (en) 2009-03-11
AR063201A1 (es) 2009-01-14
KR20090031598A (ko) 2009-03-26
JP2009542657A (ja) 2009-12-03
TW200815045A (en) 2008-04-01
WO2008005240A2 (en) 2008-01-10
NO20085158L (no) 2009-01-15
IL195161A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
US20080004329A1 (en) Pharmaceutical compositions of ropinirole and methods of use thereof
US5807568A (en) Enhanced delivery of topical compositions containing flurbiprofen
US7387788B1 (en) Pharmaceutical compositions of nicotine and methods of use thereof
CN101801359B (zh) 确保有效成分经生物界面增加释放的透皮递送设备
US20140314815A1 (en) Adhesive solid gel-forming formulations for dermal drug delivery
JP7602732B2 (ja) 片頭痛および群発頭痛の治療に適したゾルミトリプタン治療濃度を迅速に得る方法
US20090069364A1 (en) Pharmaceutical compositions of 5-alpha-reductase inhibitors and methods of use thereof
US20080138391A1 (en) Skin-friendly drug complexes for transdermal administration
PT1962817E (pt) Administração transdérmica de uma forma de sal de meptazinol
PT2116243E (pt) Composição de gel para tratamento de micoses
EP2373305B1 (en) Transdermal pharmaceutical compositions comprising a serm
JP2007536312A (ja) 抗コリン作用薬のための透過性増強組成物
US20200383910A1 (en) Topical formulation
WO2021222453A1 (en) Fast-acting topical anesthetic formulations
AU2009273211B2 (en) Transdermal pharmaceutical compositions comprising danazol
WO2008012071A2 (en) Pharmaceutical compositions of nicotine and methods of use thereof
CA2919979A1 (en) Topical compositions for treatment of excessive sweating and methods of use thereof
Arkvanshi et al. Transdermal delivery a preclinical and clinical perspective of drugs delivered via patches
Puri Enhanced delivery of actives through skin from patches and formulations, and distribution within and across skin
WAGH et al. RECENT APPROCH IN TRANSDERMAL DRUG DELIVERY SYSTEM; AN OVERVIEW
Parekh Enhancement of buccal permeation of freely soluble drug
HK1242222A1 (en) Transdermal pharmaceutical compositions comprising a serm
WO2001013938A1 (fr) Composition therapeutique pouvant etre administree par voie percutanee ou par les muqueuses

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090708